Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Compounder Inspections May Help Set New Enforcement Standard

Executive Summary

Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.


Related Content

Track And Trace: FDA Seeks Wholesaler Info Beyond Legal Requirements
GMP Flexibility For Compounders Signaled In FDA Draft Guidance
Compounding Oversight May Hinge On How FDA Treats Office Stock
Compounding Warning Letter Format Unchanged Since Legislation
Compounding Deal In Congress Allows Voluntary FDA Oversight Of Large-Scale Facilities
Compounding: FDA Stepping Up Enforcement With Warning Letters?
Compounding Oversight: Could Third-Party Inspection Solve The Problem?
Warning For Facebook “Likes” Reflects FDA Social Media Approach
NECC Crisis Festered in Ambiguity That Reigns Over Compounding
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts